Global Lower GI Series Market by applications (Gastroenteritis, Colon polyps, tumor, Strictures Crohn’s disease, lcerative colitis & others), by end users (hospitals, clinics & laboratories) & by test types (double-contrast & single-contrast): forecast to 2027
A lower GI series also said to be a lower gastrointestinal series or barium enema is one of the medical procedure which are used in the examination and diagnose with the problem related to human colon or large intestine and rectum. Lower GI series is one of the test which helps to detect the diseases and abnormalities and diagnose the symptoms such as. The lower GI series test can be examined by the X-ray pictures of patients. This examination assesses the transverse colon, ascending and right colon, the left or descending colon, the sigmoid colon and the rectum. It also includes the portion of small intestine and appendix.
The lower GI series test or barium enemas are mostly used to examine the rectum or large intestine. The lower GI series test are examine to identify and detect the diseases such as Colon polyps, tumors, Diverticular disease, Gastroenteritis, lacerative colitis or Strictures Crohn’s disease and others such as constipation, pain or blood in the stools. The lower GI series tests are widely used by the hospitals and clinics due to the large number of patients increasing across the globe.
Request for sample report at https://www.marketresearchfuture.com/sample_request/771 .
According to a recent study report published by the Market Research Future, the global market of ower GI series is expected to witness a prospective growth in terms of value with a substantial CAGR surpassing its previous growth records by the end of the forecasted period (2016 – 2027).
The global lower GI Series market has seen a prospective growth in the recent days. Earlier, the diagnoses of the diseases such as Colon polyps, tumors, diverticular disease, gastroenteritis, strictures crohn’s disease or icerative colitis was very complex and difficult to diagnose. But the invention of lower GI series test has pushed the healthcare industry to the upper level. The technological advancements, growing disposable income, rising people awareness about the lower GI series test has put a potential scope for the global lower GI series market across the globe. Increase in the number on healthcare centers, hospitals, clinics and laboratories have also driven the market. The major key challenges for this particular market are that X-rays observed and managed to give the minimum amount of radiation to create the picture. Most specialists feel that the danger is low contrasted and the advantages. Children and pregnant ladies are more touchy or sensitive to the risk and dangers of ionizing radiation.
Profiled in MRFR Analysis someof the prominent key players present in the global lower GI series test market are GastroIntestinal Endoscopy, GastroIntestinal Specialists, Eisai US, Cadila Pharmaceuticals Limited, PeaceHealth, Purdue Pharma L.P., Alfa Wassermann, NOVADAQ, Mount Sinai Beth Israel, AstraZeneca, Ironwood Pharmaceuticals and among others.
Browse Complete Report at https://www.marketresearchfuture.com/reports/lower-gi-series-market .
Lower GI Series Global Market – Segmentation
The Lower GI Series market can be segmented in to 4 key dynamics for the convenience of the report and enhanced understanding;
Segmentation by Application : Comprises – Colon polyps, tumors, Diverticular disease, Gastroenteritis, Strictures Crohn’s disease or lcerative colitis and others such as constipation, pain or blood in the stools.
Segmentation by Test Type : Comprising single-contrast technique and the double-contrast technique among others
Segmentation by End-Users : Comprising hospitals, laboratories and clinics among others.
Segmentation By Regions : Comprises Geographical regions – North America, Europe, APAC and Rest of the World.
Geographically, the lower GI series market has seen a prospective growth in the developed nation such as the US, Canada, Germany, U.K, Japan and others. The developed and advanced technologies have boosted the lower GI series market. This all regions come under the matured economy where the disposable income and people are very much aware about the different test and diseases. Even though the skilled and professional doctors, large number of hospitals and clinics, and laboratories where the lower GI series tests are available has also pushed the market. But in this region the cost of diagnose is very much high which can create a hurdle in the market growth. In Asia-Pacific, the developing region such as China, India, Singapore, Indonesia, the market has an immense opportunity to grow. In China and India, the huge population and large pool of diagnosed patients can create a scope of potential in the global lower GI series market. Huge investment for people welfare and healthcare, rising awareness are becoming the growing opportunities.